Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (78 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: syndromesclerosismonthsinjurybrain
  Phrases that lowered it: participantparticipantsvaluechildrenclinical
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: 6 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 18.1% (lowers risk) · Drug's FDA history
• Phase: 2/3 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 2 (lowers risk) · Who can join
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. NCT03715153 · started 2018 · scored riskier than 29% of active trials terminated
• Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder NCT04174365 · started 2019 · scored riskier than 24% of active trials completed
• Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) NCT03887676 · started 2019 · scored riskier than 25% of active trials completed
• A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder NCT01617447 · started 2012 · scored riskier than 8% of active trials completed
• Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO) NCT01205282 · started 2013 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.